Fig. 7. Comparisons of clinical features between the three GC subtypes.

a Kaplan–Meier curves showing that ImE and StE tend to have the best and worst survival prognosis, respectively. The log-rank test P values are shown. DFS disease-free survival. b StE harbors a higher proportion of advanced (large size/extent (T3–4), lymph nodes involved (N1–3), metastatic (M1), or late-stage (stage III–IV)) tumors than ImD and ImE. The Fisher’s exact test P values are shown. c Comparisons of the response (complete or partial response) rates of chemotherapy (30 drugs combined) and four individual chemotherapies (doxorubicin, oxaliplatin, capecitabine, and cisplatin) between the GC subtypes. ImE showing the highest response rate of chemotherapy (combined), doxorubicin, oxaliplatin, and capecitabine; ImD showing the highest response rate to cisplatin. d ImE and StE having the highest and lowest response rates to immune checkpoint inhibitors, respectively, predicted by the TIDE algorithm⁶⁸. Fisher’s exact test P values are shown.